{"analyses":[{"ciLowerLimit":"-4.44","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"17.83","groupDescription":"Event Free Rate (%) at Year 1 TC1/2/3 or IC1/2/3 ITT","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2385","paramType":"Difference in Event Free Rate","paramValue":"6.69","statisticalMethod":"Z-test"},{"ciLowerLimit":"-6.75","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"24.03","groupDescription":"Event Free Rate (%) at Year 2 TC1/2/3 or IC1/2/3 ITT","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2710","paramType":"Difference in Event Free Rate","paramValue":"8.64","statisticalMethod":"Z-test"},{"ciLowerLimit":"-5.00","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"17.67","groupDescription":"Event Free Rate (%) Year 1 TC1/2/3 or IC1/2/3 ITT WT","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2733","paramType":"Difference in Event Free Rate","paramValue":"6.34","statisticalMethod":"Z-test"},{"ciLowerLimit":"-7.44","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"24.81","groupDescription":"Event Free Rate (%) Year 2 TC1/2/3 or IC1/2/3 ITT WT","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2909","paramType":"Difference in Event Free Rate","paramValue":"8.69","statisticalMethod":"Z-test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"62.46","upperLimit":"74.66","value":"68.56"},{"groupId":"OG001","lowerLimit":"52.55","upperLimit":"71.17","value":"61.86"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"111"}],"units":"Participants"}],"title":"Event Free Rate (%) at Year 1 TC1/2/3 or IC1/2/3 ITT"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.99","upperLimit":"53.27","value":"44.63"},{"groupId":"OG001","lowerLimit":"23.25","upperLimit":"48.72","value":"35.98"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"111"}],"units":"Participants"}],"title":"Event Free Rate (%) at Year 2 TC1/2/3 or IC1/2/3 ITT"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"62.56","upperLimit":"75.13","value":"68.84"},{"groupId":"OG001","lowerLimit":"53.07","upperLimit":"71.94","value":"62.51"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"216"},{"groupId":"OG001","value":"107"}],"units":"Participants"}],"title":"Event Free Rate (%) at Year 1 TC1/2/3 or IC1/2/3 ITT WT"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34.86","upperLimit":"53.18","value":"44.02"},{"groupId":"OG001","lowerLimit":"22.06","upperLimit":"48.60","value":"35.33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"216"},{"groupId":"OG001","value":"107"}],"units":"Participants"}],"title":"Event Free Rate (%) at Year 2 TC1/2/3 or IC1/2/3 ITT WT"}],"denoms":[{"counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"111"}],"units":"Participants"}],"description":"The OS rate at the 1- and 2-year landmark time points after randomization in the PD-L1 Expression Population and PD-L1 Expression WT Population. The PD-L1 expression population is defined as one of the following: PD-L1 IHC TC1/2/3 or IC1/2/3 population, defined as ITT participants with PD-L1 IHC TC1/2/3 or IC1/2/3 expression in baseline tumor tissue; PD-L1 IHC TC2/3 or IC2/3 population, defined as ITT participants with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumor tissue; PD-L1 IHC TC3 or IC3 population, defined as ITT participants with PD-L1 IHC TC3 or IC3 expression in baseline tumor tissue. The PD-L1 expression WT population is defined as the PD-L1 expression population excluding participants with an activating EGFR mutation or ALK translocation.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.","id":"OG000","title":"Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)"},{"description":"Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.","id":"OG001","title":"Arm B (Nab-Paclitaxel+Carboplatin)"}],"paramType":"NUMBER","populationDescription":"PD-L1 Expression Population and PD-L1 Expression WT Population","reportingStatus":"POSTED","timeFrame":"Up to 35 months after first patient enrolled, years 1 and 2 reported","title":"Event Free Rate (%) at Year 1 and 2 in PD-L1 Expression Population and PD-L1 Expression WT Population","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}